146 related articles for article (PubMed ID: 34660326)
1. Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma.
Yu Z; Zhang Y; Shao S; Liu Q; Li Y; Du X; Zhang K; Zhang M; Yuan H; Yuan Q; Liu T; Gao Y; Wang Y; Hong W; Han T
Front Oncol; 2021; 11():755814. PubMed ID: 34660326
[TBL] [Abstract][Full Text] [Related]
2. Cell division cycle associated 2 (CDCA2) upregulation promotes the progression of hepatocellular carcinoma in a p53-dependant manner.
Wang J; Liu X; Chu H; Chen J
PeerJ; 2022; 10():e13535. PubMed ID: 35694386
[TBL] [Abstract][Full Text] [Related]
3. Increased CDCA2 Level Was Related to Poor Prognosis in Hepatocellular Carcinoma and Associated With Up-Regulation of Immune Checkpoints.
Tang M; Liao M; Ai X; He G
Front Med (Lausanne); 2021; 8():773724. PubMed ID: 35372372
[TBL] [Abstract][Full Text] [Related]
4. CDCA2 protects against oxidative stress by promoting BRCA1-NRF2 signaling in hepatocellular carcinoma.
Wang S; Cao K; Liao Y; Zhang W; Zheng J; Li X; Huang M; Zhong Y; Hu X; Chen D; Wang Y
Oncogene; 2021 Jun; 40(25):4368-4383. PubMed ID: 34103686
[TBL] [Abstract][Full Text] [Related]
5. TEDC2 plays an oncogenic role and serves as a therapeutic target of hepatocellular carcinoma.
Li Y; Guo B; Wang L; Zhou F; Yu Z; Huang Y; Chen R; Zhang M; Zhang K; Zheng L; Jing S; Hong W; Han T
Dig Liver Dis; 2024 May; 56(5):861-871. PubMed ID: 37867019
[TBL] [Abstract][Full Text] [Related]
6. A pan-cancer analysis reveals the diagnostic and prognostic role of CDCA2 in low-grade glioma.
Li W; Lv D; Yao J; Chen B; Liu H; Li W; Xu C; Li Z
PLoS One; 2023; 18(9):e0291024. PubMed ID: 37733705
[TBL] [Abstract][Full Text] [Related]
7. CDCA2 triggers in vivo and in vitro proliferation of hepatocellular carcinoma by activating the AKT/CCND1 signaling.
Li J; Chen Y; Wang X; Wang C
J BUON; 2021; 26(3):882-888. PubMed ID: 34268949
[TBL] [Abstract][Full Text] [Related]
8. CDCA2 Inhibits Apoptosis and Promotes Cell Proliferation in Prostate Cancer and Is Directly Regulated by HIF-1α Pathway.
Zhang Y; Cheng Y; Zhang Z; Bai Z; Jin H; Guo X; Huang X; Li M; Wang M; Shu XS; Yuan Y; Ying Y
Front Oncol; 2020; 10():725. PubMed ID: 32509575
[TBL] [Abstract][Full Text] [Related]
9. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
[TBL] [Abstract][Full Text] [Related]
10. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
11. A prognostic model for hepatocellular carcinoma based on apoptosis-related genes.
Liu R; Wang G; Zhang C; Bai D
World J Surg Oncol; 2021 Mar; 19(1):70. PubMed ID: 33712023
[TBL] [Abstract][Full Text] [Related]
12. Angiogenic Factor with G Patch and FHA Domains 1 (AGGF1) Acts as Diagnostic Biomarker and Adverse Prognostic Factor of Hepatocellular Carcinoma (HCC): Evidence from Bioinformatic Analysis.
Wang W; Zhu G; Lai S; Guo Y; Yin X; Chen D; Wen L
Med Sci Monit; 2020 Feb; 26():e919896. PubMed ID: 32090983
[TBL] [Abstract][Full Text] [Related]
13. Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma.
Wang Q; Yu X; Zheng Z; Chen F; Yang N; Zhou Y
PeerJ; 2021; 9():e11342. PubMed ID: 33987018
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic and prognostic value of cell division cycle associated gene family in Hepatocellular Carcinoma.
Wu B; Huang Y; Luo Y; Ma A; Wu Z; Gan Y; Xu Y; Xu R
J Cancer; 2020; 11(19):5727-5737. PubMed ID: 32913466
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of CDCA2 in human squamous cell carcinoma: correlation with prevention of G1 phase arrest and apoptosis.
Uchida F; Uzawa K; Kasamatsu A; Takatori H; Sakamoto Y; Ogawara K; Shiiba M; Bukawa H; Tanzawa H
PLoS One; 2013; 8(2):e56381. PubMed ID: 23418564
[TBL] [Abstract][Full Text] [Related]
17. CDCA2 promotes lung adenocarcinoma cell proliferation and predicts poor survival in lung adenocarcinoma patients.
Shi R; Zhang C; Wu Y; Wang X; Sun Q; Sun J; Xia W; Dong G; Wang A; Jiang F; Xu L
Oncotarget; 2017 Mar; 8(12):19768-19779. PubMed ID: 28423619
[TBL] [Abstract][Full Text] [Related]
18. CDT1 Is a Novel Prognostic and Predictive Biomarkers for Hepatocellular Carcinoma.
Cai C; Zhang Y; Hu X; Hu W; Yang S; Qiu H; Chu T
Front Oncol; 2021; 11():721644. PubMed ID: 34631549
[TBL] [Abstract][Full Text] [Related]
19. A novel prognostic signature based on four glycolysis-related genes predicts survival and clinical risk of hepatocellular carcinoma.
Chen Z; Zou Y; Zhang Y; Chen Z; Wu F; Shi N; Jin H
J Clin Lab Anal; 2021 Nov; 35(11):e24005. PubMed ID: 34523732
[TBL] [Abstract][Full Text] [Related]
20. The Higher Expression of CDCA2 Associated with Poor Prognosis in Glioma.
Jin X; Sun ZQ; Zhou GL; Li GJ; Deng SF
Dis Markers; 2022; 2022():2184867. PubMed ID: 35386230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
